Alnylam Pharmaceuticals Inc. (ALNY): Price and Financial Metrics
ALNY Price/Volume Stats
Current price | $149.45 | 52-week high | $218.88 |
Prev. close | $154.39 | 52-week low | $143.52 |
Day low | $149.32 | Volume | 666,500 |
Day high | $154.50 | Avg. volume | 869,823 |
50-day MA | $161.05 | Dividend yield | N/A |
200-day MA | $177.42 | Market Cap | 18.82B |
ALNY Stock Price Chart Interactive Chart >
ALNY POWR Grades
- ALNY scores best on the Quality dimension, with a Quality rank ahead of 90.03% of US stocks.
- The strongest trend for ALNY is in Stability, which has been heading down over the past 26 weeks.
- ALNY's current lowest rank is in the Momentum metric (where it is better than 18.05% of US stocks).
ALNY Stock Summary
- ALNYLAM PHARMACEUTICALS INC's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 1.46% of US listed stocks.
- Price to trailing twelve month operating cash flow for ALNY is currently 12,125.68, higher than 99.96% of US stocks with positive operating cash flow.
- ALNY's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 1.84% of US stocks.
- Stocks that are quantitatively similar to ALNY, based on their financial statements, market capitalization, and price volatility, are ATRC, BRZE, QNST, ABCL, and ACVA.
- ALNY's SEC filings can be seen here. And to visit ALNYLAM PHARMACEUTICALS INC's official web site, go to www.alnylam.com.
ALNY Valuation Summary
- ALNY's EV/EBIT ratio is -63.4; this is 534.25% lower than that of the median Healthcare stock.
- Over the past 238 months, ALNY's price/sales ratio has gone down 421.6.
Below are key valuation metrics over time for ALNY.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ALNY | 2023-12-29 | 13.9 | -144.8 | -47.1 | -63.4 |
ALNY | 2023-12-28 | 14.2 | -148.1 | -48.2 | -64.8 |
ALNY | 2023-12-27 | 14.3 | -148.7 | -48.4 | -65.1 |
ALNY | 2023-12-26 | 13.9 | -144.7 | -47.1 | -63.4 |
ALNY | 2023-12-22 | 13.9 | -144.5 | -47.0 | -63.3 |
ALNY | 2023-12-21 | 13.2 | -137.0 | -44.6 | -60.1 |
ALNY Growth Metrics
- Its 3 year net income to common stockholders growth rate is now at -11.3%.
- The 3 year cash and equivalents growth rate now stands at -26.33%.
- Its year over year price growth rate is now at 2.48%.
The table below shows ALNY's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-12-31 | 1,037.418 | -541.274 | -1,131.156 |
2022-09-30 | 960.918 | -559.437 | -1,182.123 |
2022-06-30 | 884.245 | -578.189 | -980.717 |
2022-03-31 | 879.98 | -577.226 | -892.874 |
2021-12-31 | 844.287 | -641.693 | -852.824 |
2021-09-30 | 749.314 | -614.696 | -837.904 |
ALNY's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ALNY has a Quality Grade of C, ranking ahead of 30.65% of graded US stocks.
- ALNY's asset turnover comes in at 0.22 -- ranking 188th of 681 Pharmaceutical Products stocks.
- QGEN, TXMD, and KMDA are the stocks whose asset turnover ratios are most correlated with ALNY.
The table below shows ALNY's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-09-30 | 0.220 | 0.833 | -0.249 |
2021-06-30 | 0.204 | 0.833 | -0.267 |
2021-03-31 | 0.171 | 0.832 | -0.272 |
2020-12-31 | 0.159 | 0.842 | -0.308 |
2020-09-30 | 0.141 | 0.832 | -0.372 |
2020-06-30 | 0.130 | 0.853 | -0.416 |
ALNY Price Target
For more insight on analysts targets of ALNY, see our ALNY price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $184.16 | Average Broker Recommendation | 1.64 (Moderate Buy) |
Alnylam Pharmaceuticals Inc. (ALNY) Company Bio
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics[3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.[4] In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. (Source:Wikipedia)
Latest ALNY News From Around the Web
Below are the latest news stories about ALNYLAM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ALNY as an investment opportunity.
Ionis, Astrazeneca win FDA approval of competitor to Alnylam drugThe clearance of Wainua for transthyretin amyloidosis opens up a new front in a long-running commercial battle between Ionis and Alnylam. |
13 Most Promising Healthcare Stocks According to AnalystsIn this article, we discuss the 13 most promising healthcare stocks according to analysts. To skip the detailed overview of the healthcare sector, go directly to the 5 Most Promising Healthcare Stocks According to Analysts. The healthcare industry landscape is changing. While the COVID-19 pandemic was one of the most significant events that led to […] |
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D DayCAMBRIDGE, Mass., December 13, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting a virtual R&D Day today. During the event, the Company plans to showcase its R&D progress and platform innovation, as well as its product and pipeline goals for 2024, including continued commercial execution of four RNAi therapeutic products and the advancement of early-, mid-, and late-stage investigational programs. |
Alnylam to Webcast Virtual R&D DayCAMBRIDGE, Mass., December 06, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming virtual R&D Day event on the Investors section of the Company’s website, www.alnylam.com, on Wednesday, December 13, 2023 at 8:30 am ET. A replay will be available on the Alnylam website within 48 hours after the event. |
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023CAMBRIDGE, Mass., November 30, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the "Largest Employer" category. This marks the third year in a row that Alnylam has taken the top spot in the Largest Employer category (> 1,000 employees). |
ALNY Price Returns
1-mo | -3.72% |
3-mo | -21.92% |
6-mo | -15.61% |
1-year | -23.41% |
3-year | 10.60% |
5-year | 59.93% |
YTD | -21.92% |
2023 | -19.46% |
2022 | 40.14% |
2021 | 30.48% |
2020 | 12.85% |
2019 | 57.96% |
Continue Researching ALNY
Want to do more research on Alnylam Pharmaceuticals Inc's stock and its price? Try the links below:Alnylam Pharmaceuticals Inc (ALNY) Stock Price | Nasdaq
Alnylam Pharmaceuticals Inc (ALNY) Stock Quote, History and News - Yahoo Finance
Alnylam Pharmaceuticals Inc (ALNY) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...